The European Association of Urology (EAU) PCa guidelines strongly recommend metastatic screening using PSMA-PET/CT, if available, and at least CT and bone scan for high-risk disease, while this is only a weak recommendation for men with intermediate-risk and ISUP grade 3 disease [10]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.